Rapamycin and metformin are the two most-studied repurposed drugs in longevity research. Rapamycin (an mTOR inhibitor) has the strongest cross-species lifespan-extension data in modern pharmacology - it extends lifespan in every animal model tested. Metformin (an AMPK activator and complex I inhibitor) has the strongest accumulated human safety data, with 60+ years of diabetes use behind it and the active TAME (Targeting Aging with Metformin) trial as the current human longevity read. The two target different pathways and the choice between them in research protocols is a real one with different evidence shapes on each side.
Two repurposed drugs, two different evidence shapes
Rapamycin and metformin are the two most-discussed repurposed drugs in longevity research as of 2026. Both were originally approved for unrelated indications (organ transplant rejection and type 2 diabetes respectively). Both are now studied for healthspan and potentially lifespan extension in humans. They target different pathways and have different evidence shapes.
The honest read is that they are not redundant — choosing one over the other depends on which evidence base you weight more heavily.
Mechanism
Rapamycin binds the FKBP12 protein, and the FKBP12-rapamycin complex inhibits mTOR (mechanistic target of rapamycin), a central nutrient-sensing kinase. mTOR inhibition reduces protein synthesis, increases autophagy, and modulates cellular growth signaling. The mTORC1 complex is the longevity-relevant target; chronic mTORC2 inhibition (which happens with daily dosing in transplant indications) drives most of the side-effect profile.
Metformin primarily inhibits mitochondrial respiratory complex I, which raises the AMP:ATP ratio and activates AMPK. AMPK activation suppresses gluconeogenesis (the diabetes mechanism), increases insulin sensitivity, modulates autophagy and mitochondrial biogenesis, and reduces protein synthesis through indirect effects on mTOR.
The two pathways converge at autophagy and protein synthesis modulation but enter the network at different upstream points. This is why some longevity-medicine practitioners prescribe both for the same patient — non-overlapping mechanisms.
Animal-model lifespan data
| Compound | Model organism | Result |
|---|---|---|
| Rapamycin | Yeast, worms, flies, mice | Extension in every tested species |
| Rapamycin | Mice (ITP 2009) | 9-14% lifespan extension, late-life dosing |
| Metformin | Worms (C. elegans) | Modest extension in some studies |
| Metformin | Mice (ITP) | No robust lifespan extension at standard doses |
| Metformin | Mice (Anisimov) | Lifespan extension reported, methodology disputed |
Rapamycin wins clearly on animal-model lifespan data. The cross-species replication is the strongest feature — every species tested shows extension, including the rigorous NIH ITP mouse trials. Metformin's animal-model evidence is more equivocal; the ITP did not show robust lifespan extension at typical doses.
Human evidence
Metformin wins clearly on human evidence. Decades of accumulated diabetes prescribing means there is a real population-level safety record. Observational studies in diabetic patients suggest metformin users have lower cancer incidence and lower all-cause mortality than diabetic non-users, though the causal direction is contested (the comparison group is non-users, who differ in important ways). The TAME (Targeting Aging with Metformin) trial, sponsored by the American Federation for Aging Research and led by Nir Barzilai, is the active read on metformin as a longevity intervention with formal trial methodology.
Rapamycin's human evidence is earlier-stage. Off-label longevity use has grown rapidly but in an uncontrolled way. The PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) trial is the active human read. Smaller human studies have shown immune-function improvements and other healthspan endpoints, but lifespan or all-cause mortality data in humans is not yet available.
Side-effect profile
| Side effect | Rapamycin | Metformin |
|---|---|---|
| Mouth sores (stomatitis) | Common, especially daily dosing | Rare |
| Elevated cholesterol / triglycerides | Common | Neutral or slight improvement |
| Glucose impairment | Yes (insulin resistance signal) | No - improves glucose handling |
| GI upset | Mild | Common, dose-dependent |
| Edema | Possible | Rare |
| Infection risk | Yes (immunosuppression) | No |
| B12 deficiency | No | Yes, with long-term use |
The rapamycin side-effect profile is significantly burdened by its origin as a transplant immunosuppressant. Intermittent weekly low-dose protocols studied for longevity reduce but do not eliminate these risks. Metformin's side effects are GI-dominant and mostly manageable with extended-release formulations.
Cost (off-label)
Rapamycin off-label typically runs $200-500/month at compounding-pharmacy prices for the weekly 5-10mg dose.
Generic metformin is $4-20/month at standard doses, including most pharmacy discount programs.
The cost gap is real and practical. Some research-protocol users factor cost into their selection between the two.
What this comparison does NOT settle
Three honest limitations.
No head-to-head human trial. There is no published human study comparing rapamycin and metformin for longevity outcomes. The TAME trial studies metformin alone; the PEARL trial studies rapamycin alone. The choice between them is informed by mechanism reasoning and accumulated evidence, not by direct head-to-head data.
Different evidence quality on each side. Rapamycin's strength is animal-model lifespan-extension data. Metformin's strength is accumulated human safety data. These are not directly commensurable, and reasonable longevity-medicine practitioners can reach different conclusions depending on which they weight more.
Combination therapy is unstudied. Some longevity-medicine practitioners prescribe both. The combination is not in any formal trial. Whether the mechanisms are additive, synergistic, or interfering at the cellular level is a research-protocol question that has not been answered.
Related reading
- Rapamycin peptide page — the deeper read on rapamycin's mechanism and protocol use.
- Longevity peptides 2026 — the broader compound landscape.
- NAD+ peptide page — the other major small-molecule longevity intervention.
- Best longevity telehealth platforms 2026 — where prescriber-routed longevity-drug access lives.
Sources
- Harrison DE et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009.
- Strong R et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer. Aging Cell 2016.
- Barzilai N et al. Metformin as a tool to target aging. Cell Metabolism 2016.
- Bannister CA et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014.
- Dog Aging Project — TRIAD rapamycin trial protocol.
- PEARL Trial — Participatory Evaluation of Aging with Rapamycin for Longevity.
- TAME Trial — Targeting Aging with Metformin, American Federation for Aging Research.
Frequently asked
What's the main difference between rapamycin and metformin for longevity?
Mechanism and evidence shape. Rapamycin directly inhibits mTOR (mechanistic target of rapamycin) and has cross-species lifespan-extension data - yeast, worms, flies, mice all show extension. Metformin activates AMPK and inhibits mitochondrial complex I, with much stronger accumulated human safety data (60+ years of diabetes use) but more equivocal animal-model lifespan data. They are not redundant - they target different pathways.
Which one is stronger for longevity?
Different metrics give different answers. Rapamycin has stronger animal-model lifespan-extension data, especially the 2009 NIH ITP mouse study showing 9-14% extension even with late-life dosing. Metformin has weaker animal data (the ITP did not show robust lifespan extension) but vastly more human safety data and the active TAME trial. If "stronger" means "we know it extends lifespan," rapamycin wins on the animal data. If "stronger" means "we know it's safe in humans," metformin wins on accumulated experience.
Are rapamycin and metformin FDA-approved for longevity?
No. Rapamycin (sirolimus) is FDA-approved for organ-transplant rejection and PEComa. Metformin is FDA-approved for type 2 diabetes. Longevity use of both is off-label. The TAME trial (started 2023) is the active FDA-recognized human longevity trial for metformin. There is no comparable late-stage FDA trial for rapamycin in humans, though the PEARL trial is underway.
Can you take rapamycin and metformin together?
Some longevity-medicine physicians do prescribe both off-label for the same patient because the mechanisms are non-overlapping. The combination is not formally studied in any longevity trial. Both compounds have GI side effects and the combination may increase that burden. This is a clinical decision for a prescribing physician, not a research-protocol recommendation.
What does each drug actually cost off-label?
Rapamycin off-label runs $200-500/month for the weekly 5-10mg dose at typical compounding-pharmacy prices. Generic metformin at standard 500-2000mg/day doses is $4-20/month including most pharmacy discount programs. The cost difference is a real practical factor in research-protocol selection.